QOL Medical LLC
Curt McCandless is an experienced consultant and sales specialist in the pharmaceutical industry, currently serving as an Ultra Rare Disease Consultant-Dermatology at Boehringer Ingelheim since April 2022 and as a Senior Rare Disease Specialist at QOL Medical LLC since February 2020. Prior roles include Professional Oncology Sales Representative at Syneos Health, where responsibilities included promoting treatments for oncology settings, and Territory Manager at Actelion, focusing on Valchlor for Cutaneous T-Cell Lymphoma. McCandless began their career at Merck as an Executive Sales Representative in Virology, contributing to the launch of multiple antiviral therapies. McCandless holds a Master of Arts in Public Policy Administration from Saint Louis University and a Bachelor's Degree in Business Administration from Southern Illinois University Edwardsville.
This person is not in any offices
QOL Medical LLC
OL Medical is a specialty biopharmaceutical company dedicated to improving the quality of life for patients with rare diseases, for their families, and for the physicians and caregivers who support them.QOL Medical is a patient-centric company founded in 2003 to focus on the acquisition and commercialization of orphan products in underservedmarkets. QOL Medical ensures an expanded clinical awareness and patient access for improved quality of life in the treatment of rare and orphan diseases. The Company currently markets two FDA-approved products: Sucraid® (sacrosidase) Oral Solution and Ethamolin® (Ethanolamine Oleate) Injection, 5%.QOL Medical, in its commitment to assuring safe and effective products for our customers, uses validated procedures through audited and approved vendors for manufacturing, testing, and distribution. Additionally, QOL Medical has procedures for product monitoring, customer complaints, investigations into nonconformities, and change control.